BriaCell Therapeutics (BCT.TO), up 41% in U.S. pre-market trading, on Thursday confirmed the sustained complete resolution of the lung metastasis, first reported in February, two months after initial treatment.
The latest data at four months also demonstrates stable disease elsewhere, the company said.
The patient, a 78-year-old woman with metastatic breast cancer, had failed several prior lines of therapy and received the lowest dose level in the Phase 1/2a Bria-OTS study. At enrollment last November, she had extensive metastases including bone, lymph node and lung involvement. Following Bria-OTS injections every two weeks for six weeks, and subsequent dosing every three weeks, the lung metastasis completely resolved with stable disease elsewhere. This response is now confirmed and shows the potentially promising activity of the Bria-OTS platform as monotherapy, Briacell said.
"This unprecedented anti-cancer response in the first patient dosed with Bria-OTS is an important milestone for us and provides early validation of BriaCell's personalized immunotherapy approach," said Chief Executive Dr. William Williams.
The company's shares were last seen up US$2.30, to US$7.73, in New York trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。